EGFR and non-small cell lung carcinoma: Activation of the ALK and BRAF bypass signaling pathways is a rare cause of acquired drug resistance for EGFR-TKIs.We report two NSCLC-patients with EGFR- mutations, in exon 19, and exon 18, correspondingly, who were treated with EGFR-TKIs.